Abstract:Targeted protein degradation (TPD) represents a potent chemical biology paradigm that leverages the cellular degradation machinery to pharmacologically eliminate specific proteins of interest. Although multiple E3 ligases have been discovered to facilitate TPD, there exists a compelling requirement to diversify the pool of E3 ligases available for such applications. This expansion will broaden the scope of potential protein targets, accommodating those with varying subcellular localizations and expression patterns. In this study, we describe a CRISPR-based transcriptional activation screen focused on human E3 ligases, with the goal of identifying E3 ligases that can facilitate heterobifunctional compound-mediated target degradation. This approach allows us to address the limitations associated with investigating candidate degrader molecules in specific cell lines that either lack or have low levels of the desired E3 ligases. Through this approach, we identified a candidate proteolysis-targeting chimera (PROTAC), 22-SLF, that induces the degradation of FKBP12 when the FBXO22 gene transcription is activated. 22-SLF induced the degradation of endogenous FKBP12 in a FBXO22-dependent manner across multiple cancer cell lines. Subsequent mechanistic investigations revealed that 22-SLF interacts with C227 and/or C228 in FBXO22 to achieve the target degradation. Finally, we demonstrated the versatility of FBXO22-based PROTACs by effectively degrading another endogenous protein BRD4. This study uncovers FBXO22 as an E3 ligase capable of supporting ligand-induced protein degradation through electrophilic PROTACs. The platform we have developed can readily be applied to elucidate protein degradation pathways by identifying E3 ligases that facilitate either small molecule-induced or endogenous protein degradation.

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

A CRISPR activation screen identifies FBXO22 as an E3 ligase supporting targeted protein degradation

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications

Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Discovery of electrophilic degraders that exploit SNAr chemistry

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

Targeted protein degradation: expanding the toolbox

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation